Key points for the use of other pharmacologic treatments

Patients with severe hereditary α1-antitrypsin deficiency and established emphysema may be candidates for α1-antitrypsin augmentation therapy (evidence B)
Antitussives cannot be recommended (evidence C)
Drugs approved for primary pulmonary hypertension are not recommended for patients with pulmonary hypertension secondary to COPD (evidence B)
Low-dose long acting oral and parenteral opioids may be considered for treating dyspnoea in COPD patients with severe disease (evidence B)

COPD: chronic obstructive pulmonary disease.